v3.26.1
MITOCAREX TRANSACTION (Details Narrative)
12 Months Ended
Dec. 31, 2025
USD ($)
$ / shares
Oct. 20, 2025
USD ($)
$ / shares
shares
Feb. 25, 2025
₪ / shares
Dec. 31, 2025
USD ($)
$ / shares
shares
Dec. 31, 2024
USD ($)
$ / shares
MitocarexTransactionLineItem [Line Items]          
Common stock, par value | $ / shares $ 0.0001     $ 0.0001 $ 0.0001
Short-term loan $ 740,000     $ 740,000
Shares issued price per share | $ / shares $ 1.68     $ 1.68 $ 8.68
Issuance of shares for the consideration of the acquisition   $ 4,840,000   $ 4,840,000  
Net income loss       $ (4,004,000) $ (5,193,000)
MitoCareX Bio Ltd [Member]          
MitocarexTransactionLineItem [Line Items]          
Subsidiary, ownership percentage, parent   25.00%      
Dr. Alon Silberman [Member]          
MitocarexTransactionLineItem [Line Items]          
Sale of stock issued | shares   11,166      
Sale of stock issued rate   100.00%      
Dr. Alon Silberman [Member] | Maximum [Member]          
MitocarexTransactionLineItem [Line Items]          
Maximum amount payable   $ 1,600,000      
Ciro Leonardo Pierri [Member]          
MitocarexTransactionLineItem [Line Items]          
Sale of stock issued | shares   5,584      
Sale of stock issued rate   100.00%      
Ciro Leonardo Pierri [Member] | Maximum [Member]          
MitocarexTransactionLineItem [Line Items]          
Maximum amount payable   $ 1,600,000      
Common Stock [Member]          
MitocarexTransactionLineItem [Line Items]          
Issuance of shares for the consideration of the acquisition, shares | shares   1,171,942   1,171,942 [1]  
Shares issued price per share | $ / shares   $ 4.13      
Issuance of shares for the consideration of the acquisition [2]        
SciSparc Ltd [Member]          
MitocarexTransactionLineItem [Line Items]          
Sale of stock issued | shares   12,066      
Payments of Stock Issuance Costs   $ 700,000      
SciSparc Ltd [Member] | Maximum [Member]          
MitocarexTransactionLineItem [Line Items]          
Maximum amount payable   $ 1,600,000      
SciSparc Ltd [Member] | Common Stock [Member]          
MitocarexTransactionLineItem [Line Items]          
Sale of stock issued | shares   6,622      
MitoCareX Bio Ltd [Member]          
MitocarexTransactionLineItem [Line Items]          
Short-term loan   $ 1,053,000      
Sale of stock issued rate   100.00%      
Grant of restricted stock   5.00%      
Business Combination, Consideration Transferred   $ 8,864,000      
Cash consideration   700,000      
Issuance of shares for the consideration of the acquisition   $ 4,840,000      
Fair value of contingent share consideration | shares   976,618      
Percentage of issued and outstanding capital stock   25.00%      
Contingent share consideration $ 854,000 $ 2,034,000      
Contingent cash consideration 1,287,000 $ 1,290,000      
Accrued liability $ 47,000     47,000  
MitoCareX Bio Ltd [Member] | Dr. Alon Silberman [Member]          
MitocarexTransactionLineItem [Line Items]          
Ownership percentage     30.00%    
MitoCareX Bio Ltd [Member] | Ciro Leonardo Pierri [Member]          
MitocarexTransactionLineItem [Line Items]          
Ownership percentage     30.00%    
MitoCareX Bio Ltd [Member] | SciSparc Ltd [Member]          
MitocarexTransactionLineItem [Line Items]          
Ownership percentage   30.00%      
MitoCareX [Member]          
MitocarexTransactionLineItem [Line Items]          
Net income loss       1,394 $ 886
Related party       $ 276  
Mito Agreement [Member]          
MitocarexTransactionLineItem [Line Items]          
Common stock, par value | ₪ / shares     ₪ 0.01    
[1] Adjusted to reflect one (1) for thirty-five (35) reverse stock split in September 2025 (see note 1B).
[2] Less than $1 thousand.